194 related articles for article (PubMed ID: 22639398)
1. HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes.
Heald AH; Narayanan RP; Lowes D; Jarman E; Onyekwelu E; Qureshi Z; Laing I; Anderson SG
Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):420-3. PubMed ID: 22639398
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.
Preumont V; Hermans MP; Bergman M; Buysschaert M
Acta Clin Belg; 2012; 67(6):411-5. PubMed ID: 23340146
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.
van Velsen EF; Lamers J; Blok V; van Leendert RJ; Kiewiet-Kemper RM
Neth J Med; 2014 Dec; 72(10):523-7. PubMed ID: 26219757
[TBL] [Abstract][Full Text] [Related]
4. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
5. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
[TBL] [Abstract][Full Text] [Related]
6. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity.
Preumont V; Hermans MP; Brichard S; Buysschaert M
Diabetes Metab; 2010 Sep; 36(4):293-8. PubMed ID: 20447851
[TBL] [Abstract][Full Text] [Related]
7. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
8. Exenatide versus glibenclamide in patients with diabetes.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
[TBL] [Abstract][Full Text] [Related]
9. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
10. Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
12. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
13. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
Davies MJ; Donnelly R; Barnett AH; Jones S; Nicolay C; Kilcoyne A
Diabetes Obes Metab; 2009 Dec; 11(12):1153-62. PubMed ID: 19930005
[TBL] [Abstract][Full Text] [Related]
14. Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus.
Khan M; Ouyang J; Perkins K; Nair S; Joseph F
J Diabetes Res; 2015; 2015():162718. PubMed ID: 25688374
[TBL] [Abstract][Full Text] [Related]
15. Psychological and quality of life changes in patients using GLP-1 analogues.
Grant P; Lipscomb D; Quin J
J Diabetes Complications; 2011; 25(4):244-6. PubMed ID: 21601480
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
[TBL] [Abstract][Full Text] [Related]
17. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
[TBL] [Abstract][Full Text] [Related]
19. [The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters].
Roubícek T; Mráz M; Bártlová M; Kaválková P; Haluzíková D; Trachta P; Housová J; Matoulek M; Svacina S; Haluzík M
Vnitr Lek; 2010 Jan; 56(1):15-20. PubMed ID: 20184107
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
